MOUNJARO®

Key Benefits of MOUNJARO®

MOUNJARO® delivers therapeutic efficacy by combining incretin receptor activity, resulting in improved metabolic outcomes. Its once-weekly administration simplifies treatment regimens and may contribute to improved patient adherence compared to daily therapies.

• Dual incretin receptor agonist: Activates GIP and GLP-1 receptors

• Glucose regulation: Stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, and improves insulin sensitivity

• Weight management: Modulates appetite, reduces cravings, slows gastric emptying, and supports satiety

• Dosing convenience: Weekly injection supports treatment adherence

• Device design: KwikPen® permits precise fixed-dose delivery

Clinical Indications for MOUNJARO®

MOUNJARO® is indicated for glycaemic control in adults with type 2 diabetes mellitus, either as monotherapy or as part of combination therapy. It is also approved for weight management in adults who meet defined body mass index (BMI) thresholds. Contraindications and cautions must be observed in clinical practice.

• Indications:

  • Adults with type 2 diabetes inadequately controlled with diet, exercise, or other oral antidiabetic medicines

  • Adults with BMI ≥30 kg/m² (obesity)

  • Adults with BMI ≥27 to <30 kg/m² (overweight) in the presence of at least one comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes)

• Contraindications:

  • Hypersensitivity to tirzepatide or any excipient

• Cautions:

  • History of pancreatitis

  • Presence of severe gastrointestinal disease, including gastroparesis

  • Patients with proliferative diabetic retinopathy require monitoring

• Adverse reactions (most common):

  • Nausea, diarrhoea, vomiting, abdominal pain, constipation

  • Hypoglycaemia, particularly when used with sulphonylureas or insulin

  • Injection-site reactions, including erythema or pruritus

  • Gallbladder-related events in a minority of patients

  • Rare: acute pancreatitis, serious hypersensitivity reactions

MOUNJARO® Ingredients

MOUNJARO® is formulated to ensure stability, sterility, and precise dosing. Each pre-filled pen contains tirzepatide as the active component, combined with selected excipients.

• Active substance: Tirzepatide

• Dose strength examples: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.6 mL injection

• Total content per KwikPen®: 2.4 mL (four weekly doses)

• Concentration: Varies by strength (e.g., 8.33 mg/mL for 5 mg strength, 16.7 mg/mL for 10 mg strength)

• Excipients: Includes benzyl alcohol (~5.4 mg per 0.6 mL dose)

• Sodium content: <1 mmol (23 mg) per dose, classified as sodium-free

• Appearance: Clear, colourless to slightly yellow solution

MOUNJARO® Product Range

The MOUNJARO® range provides multiple dosage strengths, allowing for progressive titration and individualised patient management. Each pen contains four fixed doses and is intended for weekly use.

• Available strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg

• Formulations: Multi-dose KwikPen®, single-patient use only

• Doses per pen: 4 pre-measured weekly injections

• Volume per injection: 0.6 mL

MOUNJARO® Administration Technique

MOUNJARO® is administered once weekly by subcutaneous injection. The device requires correct handling to ensure accurate dosing.

• Initiation: Start with 2.5 mg once weekly for 4 weeks

• Dose escalation: Increase in increments of 2.5 mg every ≥4 weeks as tolerated

• Maintenance doses: 5 mg, 10 mg, or 15 mg once weekly

• Missed dose protocol:

  • If ≤4 days late: administer as soon as possible

  • If >4 days late: skip dose and resume on next scheduled day

• Administration technique:

  • Attach new needle for each use

  • Prime pen if required

  • Dial to 1 (0.6 mL full dose)

  • Inject subcutaneously into abdomen, thigh, or upper arm

  • Depress injection button fully, hold for ≥5 seconds, confirm dose window shows 0

  • Remove and discard needle in sharps container

MOUNJARO® Storage Conditions

Correct storage is essential to maintain product stability and efficacy. Pens must be stored under refrigerated conditions until first use and then within controlled room temperature for limited time.

• Unopened pens: Store refrigerated at 2–8 °C

• Do not freeze; discard if frozen

• In-use pens: May be stored at ≤30 °C for up to 30 days

• Pen disposal: Discard after 4 doses, even if residual solution remains

• Needle storage: Never store pen with needle attached; remove after each injection

• Safety: Store out of sight and reach of children

MOUNJARO® Side Effects

The safety profile of MOUNJARO® has been characterised in clinical trials. Adverse events are primarily gastrointestinal in nature and are most pronounced during dose escalation.

Read our comprehensive article about Mounjaro side effects.

• Gastrointestinal disorders: Nausea (up to 12.2% at 5 mg), diarrhoea (11.8%), vomiting, abdominal pain, constipation

• Hypoglycaemia: Increased incidence when used with sulphonylurea or insulin; severe hypoglycaemia rare (0.2% overall)

• Injection-site reactions: Occur in 3.2–8% of patients, generally mild

• Gallbladder events: Up to 2% in weight-management trials

• Pancreatitis: Acute pancreatitis reported; discontinue if suspected

• Hypersensitivity: Rare cases of anaphylaxis or angioedema

• Laboratory changes: Mild increases in serum amylase and lipase

Buy MOUNJARO® Online

Healthcare providers and licensed purchasers can buy MOUNJARO® online or order MOUNJARO® wholesale through approved channels. Contact Medica Depot’s sales department for more information.

• Buy MOUNJARO® online for licensed clinical use

• Order MOUNJARO® wholesale in KwikPen® presentations

• Available in six strengths for titration and maintenance dosing

• Distribution restricted to professional medical channels

FAQs About MOUNJARO®

Frequently asked questions provide clarification for clinical application.

• What is MOUNJARO® used for? For type 2 diabetes and adult weight management in patients meeting BMI thresholds.

• How is it administered? By subcutaneous injection, once weekly.

• What if a dose is missed? Inject if ≤4 days late; skip if >4 days late.

• What are common side effects? Gastrointestinal reactions, hypoglycaemia (with insulin/sulphonylurea), injection-site reactions.

• How is it stored? Refrigerated prior to use; ≤30 °C for up to 30 days once in use.